TLC BioSciences

30/07/2026

TLC BioSciences 宣布 TLC590 關鍵性第三期臨床試驗完成最後一位受試者回診（Last Patient Visit）。

本試驗於美國進行，共收案304位受試者，目前已進入資料庫鎖定及數據分析階段，預計將於近期公布主要試驗結果（topline results）。

TLC590為本公司開發中的非鴉片類長效術後止痛候選產品，期待透過創新藥物傳輸技術，為術後疼痛管理提供新的治療選擇。

完整新聞稿：https://tlcbio.com/tw/news/detail/20260730

17/07/2026

As GLP-1 therapies continue to reshape healthcare, innovation in drug delivery will play an increasingly important role in expanding patient access and improving treatment experiences.

At today's BIO Asia–Taiwan 2026 Special Forum, TLC BioSciences CEO George Yeh shared perspectives on the development of long-acting GLP-1 lipid nanoparticle formulations and the opportunities ahead for next-generation therapies.

Thank you to our fellow speakers and partners for the insightful exchange of ideas.

16/07/2026

很高興看到TLC執行長 葉志鴻今日受邀參與 BIO Asia–Taiwan 2026 創新論壇「CMO Strategies」座談，與來自全球生技製藥產業的專家共同交流產業趨勢與製造策略。

隨著創新藥物與新型態藥物傳輸技術持續發展，穩健且具彈性的製造夥伴關係已成為推動生技創新的關鍵。TLC 也持續運用自身在脂質奈米藥物與脂質奈米顆粒（LNP）平台的開發經驗，推動創新療法邁向全球市場。

感謝 BIO Asia–Taiwan 提供交流平台，促進產業夥伴共同探討生技產業未來發展方向。

Pleased to see George Yeh, CEO of TLC BioSciences, participating in today's BIO Asia–Taiwan 2026 Innovation Forum panel on CMO Strategies alongside leaders from global biopharma organizations. The discussion explored manufacturing partnerships, outsourcing strategies, and opportunities to strengthen the biotech innovation ecosystem.

At TLC, we believe strong manufacturing strategies are essential to bringing innovative therapies from concept to patients around the world.

#生技產業

14/07/2026

打一針，就能啟動免疫細胞對抗癌症？

這次TLC受邀參與曲博科技教室，分享創新的 in vivo CAR-T 技術，帶大家認識癌症免疫治療的新方向。影片深入解析這項技術的原理，以及它如何有機會簡化傳統 CAR-T 的治療流程。

快來看看這項備受關注的新興技術！
🎥 https://youtu.be/q4-ipSE9MtE?si=faWwzRd4ht-nmgMu

#台微體 #癌症治療 #免疫療法 #曲博科技教室

※台微體官網👉 https://www.tlcbio.com/tw※名片App公測中！歡迎加入知識力官方Line👉 https:/...

03/07/2026

台灣生技有機會複製半導體的成功模式嗎？

在《曲博科技教室》最新專訪中，TLC 執行長葉志鴻深入介紹微脂體與脂質奈米顆粒（LNP）技術的應用，以及 TLC 如何透過藥物傳輸平台開發具有臨床價值的創新療法。
如果您對生技產業、藥物開發或新技術趨勢有興趣，歡迎收看完整訪談！

🎥 完整影片：
https://www.youtube.com/watch?v=C1KpD_-McWw&t=630s

#台微體 #微脂體 #生技產業

※台微體官網👉 https://www.tlcbio.com/tw※名片App公測中！歡迎加入知識力官方Line👉 https:/...

25/06/2026

興櫃前法人說明會現場｜TLC 管理團隊與投資人交流，聚焦公司後續發展與整體布局。

TLC BioSciences management team connecting with investors at our pre-listing conference, sharing updates on our pipeline and strategy.

23/06/2026

🚀 TLC-KY 即將登場！

我們將於 6/25 在台北出席興櫃前法人說明會，分享最新營運概況與發展方向，並與投資人面對面交流。

歡迎有興趣的投資機構預先了解活動資訊👇
活動詳情: https://tlcbio.com/tw/news/detail/20260625

19/05/2026

TLC BioSciences highlighted in Business Insider Taiwan coverage of emerging therapeutic platforms

TLC BioSciences 獲《Business Insider Taiwan》報導提及，聚焦次世代治療技術發展

🔗 https://www.businessinsider.tw/article/3002

30/04/2026

🦴 Big news from OARSI 2026 — TLC599 may do more than relieve pain.

At the OARSI 2026 World Congress on Osteoarthritis, TLC BioSciences shared exciting Phase 3 data showing that TLC599 may also slow the structural progression of knee osteoarthritis — not just reduce pain.

Patients treated with TLC599 showed approximately half the joint deterioration of those on placebo over one year. Combined with its proven 52-week pain relief, TLC599 is now emerging as a candidate for disease-modifying status — something no osteoarthritis drug has ever achieved.

For the hundreds of millions of people living with osteoarthritis worldwide, this could be a turning point. 💙

📄 Read more & access the full poster in the Pressroom at www.tlcbio.com

https://tlcbio.com/en/news/detail/OARSI2026PosterDetails

🦴 OARSI 2026 重大消息——TLC599 不只止痛，還能保護關節！
TLC BioSciences 於 OARSI 2026 世界骨關節炎大會發表 TLC599 的最新第三期臨床試驗探索性分析數據：患者關節退化速度明顯放緩，軟骨磨損幅度僅約為安慰劑組的一半。
搭配已驗證的 52 週顯著止痛效果，TLC599 展現出同時「止痛 + 保護關節」的雙重潛力，朝向全球至今仍是空白的「疾病修飾型骨關節炎藥物（DMOAD）」目標邁進。
對全球數億名受骨關節炎所苦的患者而言，這或許是改變未來治療格局的重要一步。💙

24/04/2026

As OARSI 2026 continues, conversations in osteoarthritis research are increasingly moving beyond symptom relief — toward how we define and measure long‑term joint health.

It’s an important moment for the field, and we’re pleased to be part of the scientific dialogue this week.